Vaccine Contract Manufacturing

Vaccine Contract Manufacturing

Global Vaccine Contract Manufacturing Market to Reach US$7.0 Billion by 2030

The global market for Vaccine Contract Manufacturing estimated at US$4.2 Billion in the year 2023, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Inactivated Vaccine segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 11.5% CAGR

The Vaccine Contract Manufacturing market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Vaccine Contract Manufacturing Market - Key Trends & Drivers Summarized

What Is Vaccine Contract Manufacturing, and Why Is It So Crucial in Modern Healthcare?

Vaccine Contract Manufacturing involves outsourcing vaccine production to specialized contract development and manufacturing organizations (CDMOs). These CDMOs provide end-to-end services, including process development, scale-up, bulk production, formulation, fill-finish, packaging, and quality control. Vaccine manufacturers partner with CDMOs to leverage their expertise, technology, and facilities, allowing for faster, more cost-effective production. This approach is particularly beneficial for large pharmaceutical companies looking to expand capacity and for biotech startups that need to accelerate vaccine development without building their own infrastructure.

The importance of vaccine contract manufacturing lies in its ability to rapidly scale up production, enhance flexibility, and ensure global access to vaccines, particularly in times of high demand, such as during pandemics or disease outbreaks. By enabling large-scale production, CDMOs help ensure that vaccines reach markets more quickly and at a lower cost, supporting public health initiatives worldwide. The COVID-19 pandemic underscored the critical role of contract manufacturing in meeting unprecedented global demand, with CDMOs helping pharmaceutical companies achieve faster approvals and large-scale vaccine distribution. As vaccine pipelines continue to expand and diversify—including vaccines for infectious diseases, cancer, and emerging pathogens—contract manufacturing has become indispensable in supporting efficient, reliable, and scalable vaccine production.

How Are Technological Advancements Shaping the Vaccine Contract Manufacturing Market?

Technological advancements have significantly improved the efficiency, scalability, and quality of Vaccine Contract Manufacturing, driving innovation in vaccine development and production. One of the major developments is the adoption of single-use bioreactor technology, which offers flexibility, faster turnaround times, and reduced contamination risks compared to traditional stainless-steel bioreactors. Single-use systems are particularly advantageous for producing viral vector vaccines, mRNA vaccines, and recombinant protein vaccines, allowing CDMOs to switch between different vaccine types quickly and cost-effectively.

Advancements in mRNA vaccine production have also reshaped contract manufacturing, with CDMOs investing heavily in specialized mRNA synthesis, encapsulation, and lipid nanoparticle (LNP) technologies. These innovations allow for rapid scale-up and higher yields, supporting the development of mRNA vaccines not only for COVID-19 but also for other diseases like influenza, RSV, and cancer. Automation and digitalization are transforming vaccine production lines, improving process control, reducing human error, and enabling real-time monitoring. AI and machine learning tools are being integrated into vaccine manufacturing workflows to optimize production processes, enhance batch consistency, and accelerate quality control.

Another key advancement is in fill-finish technology, where automated aseptic filling systems, lyophilization (freeze-drying), and advanced packaging solutions have improved vaccine stability, shelf life, and distribution. These innovations ensure that vaccines are produced and packaged safely and efficiently, meeting stringent regulatory standards. CDMOs are also incorporating continuous manufacturing processes, which enable uninterrupted production and real-time quality assurance, improving efficiency and reducing costs. These technological innovations not only enhance the capacity and speed of vaccine production but also align with global demands for faster, more adaptable, and scalable manufacturing solutions.

What Are the Emerging Applications of Vaccine Contract Manufacturing Across Different Vaccine Types?

Vaccine Contract Manufacturing is finding expanding applications across a diverse range of vaccine types, driven by increasing demand for specialized production capabilities. For traditional vaccines like live-attenuated, inactivated, and subunit vaccines, CDMOs provide large-scale production facilities that meet Good Manufacturing Practice (GMP) standards, ensuring high-quality and reliable output. These vaccines remain critical for routine immunization programs, targeting diseases like polio, hepatitis, and measles. Contract manufacturers play a crucial role in scaling up production to meet global immunization needs, particularly in low- and middle-income countries where vaccine access is vital for public health.

The production of next-generation vaccines, such as mRNA vaccines, DNA vaccines, and viral vector vaccines, has become a significant focus for contract manufacturing. CDMOs have rapidly adapted to support these innovative platforms, providing capabilities for mRNA synthesis, vector production, and viral encapsulation. For example, mRNA vaccines, which demonstrated rapid development and scalability during the COVID-19 pandemic, require specialized manufacturing processes that CDMOs are uniquely equipped to handle. The increasing focus on personalized cancer vaccines, which involve small-batch, patient-specific production, is also driving demand for CDMOs with flexible manufacturing setups that can accommodate small-scale, precision-focused production.

In addition to infectious disease vaccines, contract manufacturing is expanding into therapeutic vaccines targeting cancer, autoimmune diseases, and allergies. These vaccines often require complex production methods, including cell-based platforms, recombinant proteins, and novel adjuvant formulations. CDMOs are collaborating with biotech companies to develop and manufacture these therapeutic vaccines, ensuring efficient production and adherence to regulatory standards. The expanding applications of contract manufacturing across these vaccine types reflect its critical role in meeting diverse production needs, accelerating development timelines, and enabling broader access to life-saving vaccines.

What Drives Growth in the Vaccine Contract Manufacturing Market?

The growth in the Vaccine Contract Manufacturing market is driven by several factors, including the increasing demand for vaccines, the expansion of vaccine pipelines, and the need for scalable production solutions. One of the primary growth drivers is the rising global demand for vaccines, fueled by emerging infectious diseases, seasonal epidemics (e.g., influenza), and the need for mass immunization campaigns. The COVID-19 pandemic highlighted the urgency of scalable, rapid vaccine production, demonstrating the vital role of contract manufacturing in achieving global vaccination goals. As pharmaceutical companies and governments invest in pandemic preparedness and vaccine stockpiling, the reliance on CDMOs for surge capacity has increased, driving market growth.

The diversification of vaccine pipelines, with the development of mRNA, DNA, viral vector, and protein-based vaccines for both infectious diseases and therapeutic applications, has also fueled the demand for contract manufacturing. Biotech companies, startups, and academic institutions often lack the infrastructure to produce vaccines at commercial scale, making CDMOs essential partners in bringing these innovative vaccines to market. The rapid growth of mRNA vaccines beyond COVID-19—targeting conditions like influenza, RSV, Zika virus, and personalized cancer vaccines—has further driven the need for specialized contract manufacturing capabilities, including mRNA synthesis, lipid nanoparticle encapsulation, and fill-finish services.

Regulatory support and government initiatives aimed at expanding vaccine manufacturing capacity, particularly in low- and middle-income countries, have also contributed to market growth. Governments are investing in infrastructure, partnerships, and technology transfer agreements with CDMOs to ensure local production capacity and improve access to vaccines. The push for more resilient global supply chains, driven by the need to mitigate supply disruptions and improve vaccine equity, has further accelerated demand for contract manufacturing. With ongoing innovations in vaccine technologies, production methods, and digitalization, the Vaccine Contract Manufacturing market is poised for robust growth, supported by global efforts to improve public health, pandemic preparedness, and vaccine accessibility.

Select Competitors (Total 34 Featured) -
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Catalent, Inc.
  • Cobra Bio
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Icon plc
  • IDT Biologika
  • KBI Biopharma
  • Lonza
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Vaccine Contract Manufacturing – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Vaccines Drives Adoption of Contract Manufacturing Services
Expanding Role of CMOs (Contract Manufacturing Organizations) Propels Vaccine Manufacturing
Focus on Cost-Effective Vaccine Manufacturing Boosts CMO Market
Growing Role of Outsourcing in Vaccine Production Sets the Stage for CMO Growth
Regulatory Push for Faster Vaccine Approvals Drives CMO Market Expansion
Increasing Investments in Biologics Propel Vaccine Contract Manufacturing
Demand for mRNA Vaccine Production Enhances Contract Manufacturing Opportunities
Case Overview: Demand for Fill-and-Finish Services Boosts Vaccine CMO Adoption
Growing Use of Single-Use Bioprocessing in Vaccine Manufacturing Bodes Well for CMOs
Demand for High-Quality Vaccine Production Sets the Stage for CMO Market
Push for Pandemic Preparedness Drives Vaccine Contract Manufacturing
Expansion of Vaccines for Emerging Diseases Boosts CMO Demand
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Subunit-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Toxoid-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for DNA-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Veterinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Vaccine Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
JAPAN
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
CHINA
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
EUROPE
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
FRANCE
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
GERMANY
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
UNITED KINGDOM
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
AUSTRALIA
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
INDIA
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
LATIN AMERICA
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
MIDDLE EAST
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
AFRICA
Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings